glp 1 lilly Administration Anounces Landmark GLP-1 Pricing Agreement with Eli and Novo Nordisk Eli Lilly's oral GLP-1 pill

Today, I spoke live with Paul Bagnell, news anchor with Bloomberg BNN, on the topic of the GLP-1 agonists and their impact on health care, industries beyond health and medicine, and consumers

Compounded GLP-1 drugs are going away Suggested Caption: The shortage of name-brand GLP-1 drugs has ended, and less expensive compounded GLP-1 drugs will no longer be available

Discover the best fibre whilst on GLP-1 medications to manage side effects and support digestive health

Heart failure patients could be the next group to benefit from GLP-1 agonists, which are currently approved for the treatment of diabetes and obesity.

Adult-onset type 1 diabetes mellitus differs from the early onset form in terms of residual endogenous insulin secretion, comorbidities and baseline cardiorenal risk

Use of GLP-1 receptor agonists can result in unintended facial volume loss and hollowing